{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glaucoma/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field a832e622-2061-4dd7-887f-7133effc83c4 --><h2>Changes</h2><!-- end field a832e622-2061-4dd7-887f-7133effc83c4 -->","summary":null,"htmlStringContent":"<!-- begin item feb786d9-5d95-4400-be63-d3c5b8313c69 --><!-- begin field c20d0e04-816f-456b-bbb7-39506185c381 --><p><strong>November 2020 </strong>— minor update. Hallucinations added as an adverse effect of topical prostaglandin analogues in line with revised manufacturer's SPC.</p><p><strong>October 2020 </strong>— minor update. A typographical error has been corrected.</p><p><strong>May to June 2020</strong> — reviewed. A literature search was conducted in May 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field c20d0e04-816f-456b-bbb7-39506185c381 --><!-- end item feb786d9-5d95-4400-be63-d3c5b8313c69 -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","lastRevised":"Last revised in November 2020","chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","fullItemName":"Management","slug":"management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4665a282-8076-541c-8fdb-d884f514e73a","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"9418db86-0711-5f45-b026-e5fc87b633ac","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 57604f01-419c-49ab-8d03-ccdcde05b380 --><h3>Previous changes</h3><!-- end field 57604f01-419c-49ab-8d03-ccdcde05b380 -->","summary":null,"htmlStringContent":"<!-- begin item 2154ff62-e3b2-482a-b7c0-a269cbd6f187 --><!-- begin field 23efec3d-f1d1-455e-9fed-403d63966f40 --><p><strong>June 2019 </strong>— minor update. Updated in line with the guidelines <em>Glaucoma: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">NICE, 2017</a>] and <em>Glaucoma (primary angle closure) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">College of Optometrists, 2018a</a>]. </p><p><strong>February 2019 </strong>— minor update. NICE updated quality standards have been added.</p><p><strong>December 2016 </strong>— minor update.</p><ul><li>The adverse effects of brimonidine have been updated in line with the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2016a</a>].</li><li>The adverse effects of topical prostaglandin analogues have been updated in line with changes to the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2016b</a>].</li><li>A typographical error has been corrected.</li></ul><p><strong>October 2015</strong><strong> to January 2016</strong> — reviewed. A literature search was conducted in October 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring, but no major changes to the recommendations have been made.</p><p><strong>December 2014 </strong>— minor update. Additional adverse effect of periorbital and lid changes resulting in deepening of the eyelid sulcus included for topical prostaglandin analogues.</p><p><strong>July 2013</strong> — minor update. Links to the DVLA website have been updated.</p><p><strong>April 2011</strong> — minor update. NICE quality standards on the management of glaucoma added to the Goals and outcome measures section. Issued in June 2011.</p><p><strong>September 2010</strong> — minor correction to ensure the term 'chronic open angle glaucoma' is used consistently.</p><p><strong>May to September 2010</strong> — this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 23efec3d-f1d1-455e-9fed-403d63966f40 --><!-- end item 2154ff62-e3b2-482a-b7c0-a269cbd6f187 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}